Skip to main content

Table 2 Univariate and Multivariate COX Regression for Overall Survival

From: Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma

Variables

Univariate

Multivariate

P value

HR(95% CI)

P value

HR(95% CI)

Age

0.277

0.684(0.345–1.357)

  

NLR ≥ 2.4

0.362

1.375(0.694–2.725)

  

PLR ≥ 108

0.098

1.783(0.898–3.539)

  

SII ≥ 340

0.020

2.308(1.140–4.676)

0.028

2.211(1.089–4.489)

Child Pugh score 6

0.248

1.549(0.737–3.254)

  

ALBI grade 2

0.055

2.004(0.987–4.072)

  

AFP ≥ 400 ng/mL

0.008

2.849(1.309–6.200)

0.011

2.750(1.259–6.010)

PIVKA-II ≥ 1000 mAU/mL

0.079

2.122(0.917–4.913)

  

BCLC stage C

0.527

0.787(0.375–1.652)

  

Vascular invasion

0.171

1.652(0.805–3.391)

  

Extrahepatic metastasis

0.450

0.770(0.390–1.518)

  
  1. AFP alpha-fetoprotein, ALBI albumin–bilirubin, BCLC Barcelona Clinic Liver Cancer, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, PIVKA protein induced by vitamin K absence or antagonist, SII systemic immune-inflammation index